Page contentsKey factsDecisionKey facts Active Substance Sintilimab Therapeutic area Oncology Decision number P/0140/2022 PIP number EMEA-002919-PIP02-21 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of oesophageal cancer Route(s) of administration All routes of administration Contact for public enquiries Eli Lilly and Company LimitedE-mail: eu_paediatric@lilly.comTel. +44 (0)1276 483000 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 13/04/2022DecisionP/0140/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for sintilimab (EMEA-002919-PIP02-21)AdoptedReference Number: EMA/157578/2022 English (EN) (184.39 KB - PDF)First published: 17/04/2023ViewShare this page